Showing interferon type, indications and time to diagnosis of pericardial injury
| n | Author/year | Interferon type | Indication | Dose | Duration of treatment | Time to diagnosis | Autoimmune markers |
|---|---|---|---|---|---|---|---|
| 1 | Fava/1996 | IFN-α | CML | 9 x106 U daily | 10 M | 3 M AD | ANA (+) |
| 2 | Boonen/1999 | IFN-α | Hepatitis C | 3 x106 U 3 wk | 17 M | 17 M AS | ANA (+), ds-DNA (+) (SLE) |
| 3 | Gressens/2004 | IFN-α2b | Hepatitis C | 3 x106 U 3 wk | 12 M | 4 M AD | NA |
| 4 | Benjamini/2007 | IFN-α2b | Malignant melanoma | 18×106 U daily | 30 D | 30 D AS | NA |
| 5 | Nishoi/2010 | IFN-α2b | Hepatitis C | 180 μg a wk | 14 days | 14 D AS | ANA (+), ds-DNA (+) |
| 6 | Popescu/2011 | Peg IFN-α2b | Hepatitis C | 180 μg a wk | 7 M | 7 M AS | NA |
| 7 | Rauw/ 2012 | IFN-α2b | Malignant melanoma | 32×106 U daily | 5 D | 5 D AS | ANA (+) (limited scleroderma) |
| 8 | Hakim/2013 | Peg IFN-α2b | PRV | 60 μg a wk | 15 M | 15 M | ANA (−), ds-DNA (−), RF (−) Anti-GBM (−), ANCA (−) |
(–), negative; (+), positive; 3 wk, three times a week; μg, microgram; AD, after discontinuation of interferon; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibody; anti-GBM, antiglomerular basement ant; AS, after starting inteferon; CML, chronic myelogenous leukaemia; D, days; ds-DNA, double-strand deoxyribonucleotide acid; IFN, interferon; M, month; n, case number; Peg, pegylated; PRV, polycythaemia rubra vera; RF, rheumatoid factor; SLE, systemic lupus erythematosus; U, units; wk, week.